---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-006483"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T07:52:53.196597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone launches CARDAMYST nasal spray for PSVT via U.S. retail pharmacies

## Summary
- CARDAMYST (etripamil) is now available through U.S. retail pharmacies as first self-administered PSVT treatment.
- National sales force deployment set for mid-February 2026 to support commercialization.
- Eligible commercially insured patients receive a $25 copay cap via patient assistance program.
- FDA approved CARDAMYST on December 12, 2025 — first PSVT therapy approved in over 30 years.

## SEC filing metadata
- accession: 0001104659-26-006483
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/0001104659-26-006483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/tm263973d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-006483
- JSON: https://secwatch.observer/filing/0001104659-26-006483.json
- Plain text: https://secwatch.observer/filing/0001104659-26-006483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.